Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY231 in Relapsed/Refractory B-cell Malignancies
NCT07065279Phase 1Recruiting
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JY231 in B cell malignancies. Primary endpoints: Maximal Tolerated Dose at 28 days and Incidence of Adverse Events at 24 months. Started Jul 2025; status: recruiting.
02
Drugs
JY231
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT07065279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065279.